SAR439459 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 274 | Osteogenesis Imperfecta | 1 |
274. Osteogenesis Imperfecta
Clinical trials : 91 / Drugs : 101 - (DrugBank : 20) / Drug target genes : 11 - Drug target pathways : 48
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05231668 (ClinicalTrials.gov) | August 25, 2022 | 31/1/2022 | Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI) | A Phase 1b, Single Ascending Dose, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Activity of SAR439459 in Adults With Osteogenesis Imperfecta | Osteogenesis Imperfecta | Drug: SAR439459;Drug: Placebo | Sanofi | NULL | Recruiting | 18 Years | 65 Years | All | 24 | Phase 1 | United States;Australia;Canada;France |